Santo Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

Santo Therapeutics General Information

Description

Developer of gene therapy platforms focused on enhancing drug safety, production efficiency, and treatment accessibility. The company's technologies include a lentiviral vector delivery system, disease modelling tools and process optimisation frameworks, enabling advanced gene therapy development while reducing costs and expanding patient access.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 1001, 10th Floor, Unit 1, Building 30, Phase I, Qianwan Bio-harbor
  • Ningwei Street, Xiaoshan District
  • Hangzhou, Zhejiang 214000
  • China
+86 130
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Corporate Office
  • Room 1001, 10th Floor, Unit 1, Building 30, Phase I, Qianwan Bio-harbor
  • Ningwei Street, Xiaoshan District
  • Hangzhou, Zhejiang 214000
  • China
+86 130

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Santo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 27-Sep-2025 Completed Generating Revenue
4. Early Stage VC 29-Dec-2023 Completed Generating Revenue
3. Secondary Transaction - Private 17-Mar-2022 Completed Generating Revenue
2. Seed Round 19-Jul-2021 Completed Generating Revenue
1. Secondary Transaction - Private 26-Apr-2021 Completed Generating Revenue
To view Santo Therapeutics’s complete valuation and funding history, request access »

Santo Therapeutics Patents

Santo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024431508-A1 Lentiviral vector for gene therapy of neurofibromatosis type 2, and use thereof Pending 29-Feb-2024
WO-2025179891-A1 Lentiviral vector for gene therapy of neurofibromatosis type 2, and use thereof Pending 29-Feb-2024

Santo Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Shanghai Kindly Enterprise Development Group Company Corporation Minority
Transfar Capital Corporation Minority
Triwise Capital Venture Capital Minority
Shanghai Dragon Boat Investment Management Venture Capital Minority
To view Santo Therapeutics’s complete investors history, request access »

Santo Therapeutics FAQs

  • When was Santo Therapeutics founded?

    Santo Therapeutics was founded in 2020.

  • Where is Santo Therapeutics headquartered?

    Santo Therapeutics is headquartered in Hangzhou, China.

  • What industry is Santo Therapeutics in?

    Santo Therapeutics’s primary industry is Drug Discovery.

  • Is Santo Therapeutics a private or public company?

    Santo Therapeutics is a Private company.

  • What is Santo Therapeutics’s current revenue?

    The current revenue for Santo Therapeutics is .

  • Who are Santo Therapeutics’s investors?

    Shanghai Kindly Enterprise Development Group Company, Transfar Capital, Triwise Capital, and Shanghai Dragon Boat Investment Management have invested in Santo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process